<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1442</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9808199</PubmedId>
            <Abstract>This study identifies instability of MHC class I/peptide complexes and intermolecular competition for MHC class I presentation as factors responsible for the subdominance of cytotoxic T lymphocyte (CTL) epitopes. This evidence is based on the characterization of a new CTL epitope derived from the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV). This epitope, peptide GP117-125 (GP117) is presented to T cells by the mouse MHC class I molecule, H-2Db. In short-term experiments induction of GP117-specific CTL by vaccination rendered C57BL/6 mice only partially resistant to infection with wild-type LCMV (LCMV-WE) but completely resistant to challenge with a previously described LCMV variant. The variant virus, LCMV-8.7B23, bears point mutations within both known LCMV-GP, H-2 Db-restricted epitopes GP33-41 (GP33) and GP276-286 (GP276) resulting in a valine to leucine change at position 35 in peptide GP33 (V35L) and an asparagine to serine change at position 280 in peptide GP276 (N280S). Although variant peptide GP33/V35L stimulates a weak CTL response, GP276/N280S does not. Elution of peptide GP117 from both LCMV-WE- and LCMV-8.7B23-infected cells revealed that the difference in the capacity of GP117-specific CTL to protect against LCMV-WE and the virus variant LCMV-8.7B23 was due to differences in the level of GP117 presentation on the surface of both types of cells. Thus, it appears that the protective capacity of CTL specific for the subdominant epitope GP117 is influenced by the extent of presentation of other immunodominant peptide epitopes present within infected cells.</Abstract>
            <ArticleYear>1998</ArticleYear>
            <ArticlePages>3301-11</ArticlePages>
            <ArticleTitle>A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gallimore</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Hombach</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Dumrese</LastName>
                    <ForeName>T</ForeName>
                </Author>
                <Author>
                    <LastName>Rammensee</LastName>
                    <ForeName>H G</ForeName>
                </Author>
                <Author>
                    <LastName>Zinkernagel</LastName>
                    <ForeName>R M</ForeName>
                </Author>
                <Author>
                    <LastName>Hengartner</LastName>
                    <ForeName>H</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Experimental Immunology, ZÃ¼rich, Switzerland. awen.gallimore@ndm.ox.ac.uk.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;H-2 Antigens;Histocompatibility Antigen H-2D;Peptides;Recombinant Fusion Proteins;Viral Proteins;DNA</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Base Sequence; Cell Line; DNA; Epitope Mapping; Epitopes, T-Lymphocyte(immunology); Genetic Vectors; H-2 Antigens(immunology); Histocompatibility Antigen H-2D; Immunization; Lymphocytic choriomeningitis virus(immunology); Mice; Mice, Inbred C57BL; Molecular Sequence Data; Peptides(immunology); Recombinant Fusion Proteins(genetics; immunology); T-Lymphocytes, Cytotoxic(immunology); Vaccinia virus; Viral Proteins(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>28</Volume>
                <Issue>10</Issue>
                <Title>European journal of immunology</Title>
                <Issn>0014-2980</Issn>
                <MedlineTa>Eur J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>GP117-125</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ILNHNFCNL</LinearSequence>
                        <StartingPosition>117</StartingPosition>
                        <EndingPosition>125</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P07399.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11627</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3307</LocationOfData>
                <EpitopeId>27229</EpitopeId>
                <ReferenceStartingPosition>117</ReferenceStartingPosition>
                <ReferenceEndingPosition>125</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>GP117-125 represents a subdominant epitope presented to CTL in the context of MHC class I during LCMV infection.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3b</LocationOfData>
                        <TCellId>22804</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11627</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain WE)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized by infection with LCMV-WE or LCMV-8.7B23 for 8 days.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP117-125</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ILNHNFCNL</LinearSequence>
                                        <StartingPosition>117</StartingPosition>
                                        <EndingPosition>125</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07399.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11627</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>GP117-specific CTL cytotoxicity was observed during acute phase of LCMV-WE and LCMV-8.7B23 infection using spleen cells assayed ex vivo from infected mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3a</LocationOfData>
                        <TCellId>22803</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000489</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>LCMV 8.7B23</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized by infection with LCMV-8.7B23 for 8 days.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>MHC binding assay</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP117-125</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ILNHNFCNL</LinearSequence>
                                        <StartingPosition>117</StartingPosition>
                                        <EndingPosition>125</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07399.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11627</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>GP117-specific CTL cytotoxicity was observed during acute phase of LCMV-8.7B23 infection using spleen cells assayed ex vivo from LCMV-8.7B23 infected mice.  In data not shown, spleen cells assayed ex vivo from LCMV 8.7B23 infected mice were also able to lyse GP117-125-pulsed targets in the context of H-2Db, but not H-2Kb.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcLigandElution>
                        <LocationOfData>Figure 6a</LocationOfData>
                        <MhcLigandElutionId>22801</MhcLigandElutionId>
                        <HostOrganism>
                            <OrganismId>10090</OrganismId>
                        </HostOrganism>
                        <InVivoProcess>
                            <InVivoProcessType>No immunization</InVivoProcessType>
                        </InVivoProcess>
                        <InVitroAdministration>
                            <ProcessType>Antigen administered in vitro</ProcessType>
                            <ProcessedAntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11627</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </ProcessedAntigenObject>
                            <ProcessedAntigenEvidenceCode>Exact match to reference information</ProcessedAntigenEvidenceCode>
                        </InVitroAdministration>
                        <MhcLigand>
                            <MhcLigandReferenceName>GP117-125</MhcLigandReferenceName>
                            <MhcLigandObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ILNHNFCNL</LinearSequence>
                                        <StartingPosition>117</StartingPosition>
                                        <EndingPosition>125</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07399.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11627</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </MhcLigandObject>
                        </MhcLigand>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Antibody purification</MhcEvidenceCode>
                        </MhcAllele>
                        <AssayInformation>
                            <AssayTypeId>92</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Naturally processed peptides were eluted from LCMV 8.7B23 and LCMV-WE infected MC57 cells using immunoaffinity chromatography.  Each positive fraction co-eluted with synthetic peptide.  Naturally eluted peptide fractions were able to sensitize targets to lysis using GP117-specific CTL.  However, GP117-specific CTL were unable to recognize peptides eluted from LCMV-WE infected cell fractions.</AssayComments>
                        </AssayInformation>
                    </MhcLigandElution>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24213</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The rate of dissociation (half life) for the Db/GP117-125 complexes was less than 2 hours.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>22531</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Human cell lines transfected with murine Db class I molecules were incubated with GP117 to determine binding stablility.  GP117 found to stabilize cell surface expression of H-2 Dd as efficiently as other pre-established peptides representing dominant epitopes.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP33-41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P07399.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11627</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3307</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>41</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The major CTL epitope GP33-41 (H-2Db and H-2Kb) was previously established.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24198</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Human cell lines transfected with murine Db class I molecules were incubated with GP33-41 to determine binding stablility.  GP33 found to stabilize cell surface expression of H-2 Dd efficiently.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24214</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The dissociation rate for the Db/GP33-41 complexes was greater than 4 hours.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP276-286</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                        <StartingPosition>276</StartingPosition>
                        <EndingPosition>286</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P07399.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11627</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3307</LocationOfData>
                <EpitopeId>58282</EpitopeId>
                <ReferenceStartingPosition>276</ReferenceStartingPosition>
                <ReferenceEndingPosition>286</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The major CTL epitope GP276-286 (H-2Db) was previously established.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24199</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Human cell lines transfected with murine Db class I molecules were incubated with GP276-286 to determine binding stablility.  GP276 found to stabilize cell surface expression of H-2 Dd efficiently.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24215</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The dissociation rate for the Db/GP276-286 complexes was greater than 4 hours.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP396-404</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FQPQNGQFI</LinearSequence>
                        <StartingPosition>396</StartingPosition>
                        <EndingPosition>404</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P07400.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11627</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3307</LocationOfData>
                <EpitopeId>17516</EpitopeId>
                <ReferenceStartingPosition>396</ReferenceStartingPosition>
                <ReferenceEndingPosition>404</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The major CTL epitope NP396-404 (H-2Db) was previously established.</EpitopeComments>
                <Assays>
                    <MhcLigandElution>
                        <LocationOfData>Figure 6</LocationOfData>
                        <MhcLigandElutionId>24201</MhcLigandElutionId>
                        <HostOrganism>
                            <OrganismId>10090</OrganismId>
                        </HostOrganism>
                        <InVivoProcess>
                            <InVivoProcessType>No immunization</InVivoProcessType>
                        </InVivoProcess>
                        <InVitroAdministration>
                            <ProcessType>Antigen administered in vitro</ProcessType>
                            <ProcessedAntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11627</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </ProcessedAntigenObject>
                            <ProcessedAntigenEvidenceCode>Exact match to reference information</ProcessedAntigenEvidenceCode>
                        </InVitroAdministration>
                        <MhcLigand>
                            <MhcLigandReferenceName>NP396-404</MhcLigandReferenceName>
                            <MhcLigandObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FQPQNGQFI</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>404</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P07400.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11627</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </MhcLigandObject>
                        </MhcLigand>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Antibody purification</MhcEvidenceCode>
                        </MhcAllele>
                        <AssayInformation>
                            <AssayTypeId>92</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Naturally processed peptides were eluted from LCMV 8.7B23 and LCMV-WE infected MC57 cells using immunoaffinity chromatography.  Each positive fraction co-eluted with synthetic peptide.  Naturally eluted peptide fractions from both virus strains were able to sensitize targets to lysis using NP396-404-specific CTL.</AssayComments>
                        </AssayInformation>
                    </MhcLigandElution>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24216</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The dissociation rate for the Db/NP396-404 complexes was greater than 4 hours.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcBindingId>24200</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Human cell lines transfected with murine Db class I molecules were incubated with NP396-404 to determine binding stablility.  NP396 found to stabilize cell surface expression of H-2 Dd efficiently.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

